Event
Women in TPD Europe
Date: 11 March 2026
Location: London, UK
Katie Headland, Senior Director
Business Development UK
Axxam at Women in TPD Europe
Axxam will participate in Women in TPD Europe, a conference dedicated to advancing innovation and collaboration in the field of targeted protein degradation (TPD).
Our Senior Director, Business Development UK, Katie Headland, will attend the event and will be available to discuss collaboration opportunities with pharmaceutical, biotechnology, and academic partners working on next-generation therapeutic strategies based on protein degradation technologies.
The event brings together researchers, industry leaders, and emerging voices in the TPD field to exchange ideas, share scientific insights, and strengthen the role of women in this rapidly growing area of drug discovery.
About Women in TPD Europe
Women in TPD Europe is a scientific and networking event focused on the rapidly evolving field of targeted protein degradation, a therapeutic strategy that aims to selectively eliminate disease-relevant proteins rather than simply inhibiting their activity.
The conference provides a platform for scientists and industry professionals to discuss:
- new approaches in protein degradation technologies
- advances in PROTACs, molecular glues, and degrader molecules
- discovery strategies and screening technologies
- translational approaches for drug discovery
- collaboration opportunities across academia, biotech, and pharma
In addition to scientific exchange, the event also promotes visibility, mentorship, and leadership for women in the TPD community, encouraging collaboration and knowledge sharing across the life sciences ecosystem.
Targeted Protein Degradation in Drug Discovery
Targeted protein degradation has emerged as a powerful therapeutic strategy capable of addressing previously undruggable targets. By harnessing the cell’s natural protein degradation machinery, degrader molecules can selectively remove disease-causing proteins.
Developing these approaches requires robust discovery platforms, advanced screening technologies, and high-quality biological data to identify and characterize new degrader molecules.
At Axxam, we support drug discovery programs through integrated discovery services, including:
- assay development and optimization
- Cell-based and cell-free assays
- high-throughput screening (HTS)
- mechanism-of-action studies
- compound profiling and characterization
These capabilities enable partners to accelerate the identification and validation of new therapeutic opportunities.
g.
Meet Axxam at the Event
If you are attending Women in TPD Europe, this is a great opportunity to connect with our team.
Katie, Senior Director Business Development UK, will be present to discuss:
- discovery collaborations
- assay development strategies
- screening campaigns supporting degrader discovery
We look forward to meeting researchers and industry professionals working to advance targeted protein degradation as a therapeutic strategy.